STOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025 resolved on directed issues of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class...
Related Questions
What is the expected effect of the directed issue of redeemable and convertible class C shares on Sobi's capital structure?
How will the authorized repurchase of all issued class C shares influence liquidity and shareholder dilution?
What are the potential market reactions and price volatility surrounding the AGM resolutions and subsequent share actions?